問卷

TPIDB > Search Result

Search Result

篩選

List

1858Cases

2022-06-01 - 2024-10-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2020-08-14 - 2027-07-24

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2016-04-04 - 2024-05-12

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-09-01 - 2025-07-29

Phase II

Completed
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
  • Condition/Disease

    Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

  • Test Drug

    NIS793PDR001

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2022-08-12 - 2027-02-20

Phase III

Active
A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    JDQ443

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated2Sites

2024-09-01 - 2030-10-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-10-01 - 2032-08-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-01-09 - 2024-10-08

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2010-07-01 - 2011-07-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2006-11-01 - 2010-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites